Associations between single-nucleotide polymorphisms of the VEGF gene and long-term prognosis of oral squamous cell carcinoma

Journal of Oral Pathology and Medicine

Volumn 42, Issue 5, 2013, Pages 374-381

  Kammerer P W ^a,b,c   Koch, F P ^b   Schiegnitz, E ^b   Kumar, V V ^b,c   Berres, M ^b   Toyoshima, T ^d   Al Nawas, B ^b   Brieger, J ^e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c MR Ambedkar Dental college and hospital   (India)

^d KYUSHU UNIVERSITY   (Japan)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Advanced; Long term; Oral squamous cell carcinoma; Prognosis; Single nucleotide polymorphisms; Smoking; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; ORAL SURGERY; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SECOND CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SURVIVAL TIME; TUMOR VOLUME;

ADENOSINE; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYTOSINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENOTYPE; GUANINE; HAPLOTYPES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RETROSPECTIVE STUDIES; SMOKING; SURVIVAL RATE; THYMINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84876720446     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12026     Document Type: Article

References (54)

1. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.
2. Linderholm B, Lindh B, Tavelin B, Grankvist K, Henriksson R. p53, vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer 2000; 89: 51-62.
3. Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997; 89: 139-47.
4. Kaio E, Tanaka S, Kitadai Y, et al. Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 2003; 64: 61-73.
5. Jain L, Vargo CA, Danesi R, et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 2009; 8: 2496-508.
6. Yapijakis C, Vairaktaris E, Vassiliou S, et al. The low VEGF production allele of the +936C/T polymorphism is strongly associated with increased risk for oral cancer. J Cancer Res Clin Oncol 2007; 133: 787-91.
7. Ku KT, Wan L, Peng HC, Tsai MH, Tsai CH, Tsai FJ. Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for oral cancer. Oral Oncol 2005; 41: 497-502.
8. Cheng CY, Chang CS, Liu CJ, Kao SY. Vascular endothelial growth factor 936 C/T polymorphism is associated with vascular invasion in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 106: 79-84.
9. Hong TT, Zhang RX, Wu XH, Hua D. Polymorphism of vascular endothelial growth factor -1154G>A (rs1570360) with cancer risk: a meta-analysis of 16 case-control studies. Mol Biol Rep 2012; 39: 5283-9.
10. Cao C, Fang JJ, Ying T, et al. Vascular endothelial growth factor +936C/T and +405G/C polymorphisms and cancer risk: a meta-analysis. Arch Med Res 2010; 41: 548-57.
11. Zhang C, Li JP, Zhou P. Vascular endothelial growth factor (VEGF) +936 C/T gene polymorphism and gastric cancer risk: appraisal of a recent meta-analysis. Int J Biol Markers 2011; 26: 274-5.
12. Diaz-Padilla I, Amir E, Marsh S, Liu G, Mackay H. Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: a systematic review. Gynecol Oncol 2012; 124: 354-65.
13. Llewellyn CD, Linklater K, Bell J, Johnson NW, Warnakulasuriya S. An analysis of risk factors for oral cancer in young people: a case-control study. Oral Oncol 2004; 40: 304-13.
14. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin 2002; 52: 195-215.
15. Kämmerer PW, Toyoshima T, Eletr S, et al. Single nucleotide polymorphisms of the vascular endothelial growth factor gene associated with incidence of oral squamous cell carcinoma. J Oral Pathol Med 2010; 39: 786-92.
16. Bradbury PA, Zhai R, Ma C, et al. Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin Cancer Res 2009; 15: 4680-5.
17. Heist RS, Zhai R, Liu G, et al. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 856-62.
18. Lu H, Shu XO, Cui Y, et al. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res 2005; 65: 5015-9.
19. Dassoulas K, Gazouli M, Rizos S, et al. Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog 2009; 48: 563-9.
20. Kawai Y, Sakano S, Korenaga Y, Eguchi S, Naito K. Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur Urol 2007; 52: 1147-55.
21. Diao LP, Yu XM, Gao YH, et al. Association of VEGF genetic polymorphisms with the clinical characteristics of non-Hodgkin's lymphoma. J Cancer Res Clin Oncol 2009; 135: 1473-81.
22. Polterauer S, Grimm C, Mustea A, et al. Vascular endothelial growth factor gene polymorphisms in ovarian cancer. Gynecol Oncol 2007; 105: 385-9.
23. Howell WM, Bateman AC, Turner SJ, Collins A, Theaker JM. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun 2002; 3: 229-32.
24. Savas S. A curated database of genetic markers from the angiogenesis/VEGF pathway and their relation to clinical outcome in human cancers. Acta Oncol 2012; 51: 243-6.
25. Supic G, Jovic N, Zeljic K, Kozomara R, Magic Z. Association of VEGF-A genetic polymorphisms with cancer risk and survival in advanced-stage oral squamous cell carcinoma patients. Oral Oncol 2012; 48: 1171-7.
26. Declaration of Helsinki-ethical principles for medical research involving human subjects (2011).
27. Kämmerer PW, Toyoshima T, Schöder F, et al. Association of T cell regulatory gene polymorphisms with oral squamous cell carcinoma. Oral Oncol 2010; 46: 543-8.
28. Masago K, Fujita S, Kim YH et al. Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer. Cancer Sci 2009; 100: 1917-22.
29. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000; 37: 443-8.
30. Schneider BP, Radovich M, Miller KD. The role of vascular endothelial growth factor genetic variability in cancer. Clin Cancer Res 2009; 15: 5297-302.
31. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 2004; 46: 293-8.
32. Mohammadi M, Bazrafshani MR, Day PJ, Ollier WE. Vascular endothelial growth factor production is regulated by gene polymorphisms. Iran J Immunol 2009; 6: 119-29.
33. Shahbazi M, Fryer AA, Pravica V, et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002; 13: 260-4.
34. Burstein HJ, Chen YH, Parker LM, et al. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 2008; 14: 7871-7.
35. Dudek AZ, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest 2005; 23: 193-200.
36. Eroglu A, Gulec S, Kurtman C, Cam R, Akar N. Vascular endothelial growth factor 936 C/T polymorphism in cancer patients. Ann Oncol 2006; 17: 1467-8.
37. Lurje G, Zhang W, Schultheis AM, et al. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol 2008; 19: 1734-41.
38. McCarron SL, Edwards S, Evans PR, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002; 62: 3369-72.
39. Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008; 26: 4672-8.
40. Koutras AK, Antonacopoulou AG, Eleftheraki AG et al. Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. Pharmacogenomics J 2012; 12: 468-75.
41. Steffensen KD, Waldstrom M, Brandslund I, Jakobsen A. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol 2010; 117: 109-16.
42. Vincenti V, Cassano C, Rocchi M, Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996; 93: 1493-5.
43. Al-Moundhri MS, Al-Nabhani M, Burney IA, Al-Farsi AA, Al-Bahrani B. Gastric cancer risk predisposition and prognostic significance of vascular endothelial growth factor (VEGF) gene polymorphisms-a case-control study in an Omani population. Mol Carcinog 2009; 48: 1170-6.
44. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003; 63: 812-6.
45. Hansen TF, Spindler KL, Lorentzen KA, et al. The importance of -460 C/T and +405 G/C single nucleotide polymorphisms to the function of vascular endothelial growth factor A in colorectal cancer. J Cancer Res Clin Oncol 2010; 136: 751-8.
46. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 2000; 12: 1232-5.
47. Wang YH, Yeh SD, Wu MM et al. Comparing the joint effect of arsenic exposure, cigarette smoking and risk genotypes of vascular endothelial growth factor on upper urinary tract urothelial carcinoma and bladder cancer. J Hazard Mater 2012; pii: S0304-3894(12)00871-0. doi: 10.1016/j.jhazmat.2012.08.056. [Epub ahead of print].
48. Fielding S, Short C, Davies K, Wald N, Bridges BA, Waters R. Studies on the ability of smoke from different types of cigarettes to induce DNA single-strand breaks in cultured human cells. Mutat Res 1989; 214: 147-51.
49. Chen Y, Dawes PT, Mattey DL. Polymorphism in the vascular endothelial growth factor A (VEGFA) gene is associated with serum VEGF-A level and disease activity in rheumatoid arthritis: differential effect of cigarette smoking. Cytokine 2012; 58: 390-7.
50. Chen Y, Dawes PT, Packham JC, Mattey DL. Interaction between smoking and polymorphism in the promoter region of the VEGFA gene is associated with ischemic heart disease and myocardial infarction in rheumatoid arthritis. J Rheumatol 2011; 38: 802-9.
51. Zhai R, Liu G, Asomaning K, et al. Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk. Carcinogenesis 2008; 29: 2330-4.
52. Conklin BS, Zhao W, Zhong DS, Chen C. Nicotine and cotinine up-regulate vascular endothelial growth factor expression in endothelial cells. Am J Pathol 2002; 160: 413-8.
53. Kanda Y, Watanabe Y. Nicotine-induced vascular endothelial growth factor release via the EGFR-ERK pathway in rat vascular smooth muscle cells. Life Sci 2007; 80: 1409-14.
54. Schiegnitz E, Kämmerer PW, Koch FP, Krüger M, Berres M, Al-Nawas B. GDF 15 as an anti-apoptotic, diagnostic and prognostic marker in oral squamous cell carcinoma. Oral Oncol 2012; 48: 608-14.